Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. director Rajeev Kumar Bakshi reported new equity awards. On 01/14/2026 he received 7,241 restricted stock units of common shares at no purchase price, which vest one year from the grant date. He was also granted 8,437 common share options with a conversion or exercise price of $6.56 per share; these options also vest one year from the grant date.
After these awards, he beneficially owns 12,283 common shares directly and 6,801 common shares indirectly through Vincorp Holdings Ltd., plus 8,437 stock options that can be exercised into common shares once vested.
Alpha Cognition Inc. reported that its Compensation Committee granted new equity awards to senior executives under the 2025 Stock and Incentive Plan on January 9, 2026. These long-term incentives are structured as a mix of restricted stock units (RSUs), stock options, and, for the CEO, performance-based share units.
Chief Executive Officer Michael McFadden received 190,549 RSUs vesting in three equal annual installments from January 9, 2027 to January 9, 2029, 177,576 stock options vesting one-third on January 9, 2027 and quarterly thereafter, and 76,220 performance share units that can vest over two years if the share price reaches levels from $12.00 up to $28.00 for specified trading periods. Chief Operating Officer Lauren D’Angelo received 137,195 RSUs and 106,545 stock options with similar time-based vesting, while Interim Chief Financial Officer Henry Du received 20,579 RSUs and 15,982 stock options on the same vesting schedule.
Alpha Cognition Inc. reported that Chief Executive Officer and director Michael E. McFadden received multiple equity awards on January 9, 2026. He was granted 190,549 restricted stock units at a price of $0, which vest in three equal parts on January 9, 2027, January 9, 2028, and January 9, 2029. He also received 177,576 common share options with an exercise price of $6.56, vesting one‑third on January 9, 2027 and the rest in equal quarterly installments until expiration on January 13, 2036. In addition, he was granted 76,220 performance share units with a conversion price of $6.56, vesting after a two‑year period if the company’s stock meets specified price levels for at least twenty trading days within rolling thirty‑day periods. Following these grants, he directly beneficially owned 190,549 common shares and held 14,142 common shares indirectly through The Michael and Sherri McFadden Family Trust.
Alpha Cognition Inc. Chief Operating Officer Lauren D'Angelo received equity awards on January 9, 2026. The filing shows she was granted 137,195 common shares in the form of restricted stock units at a price of $0, vesting one-third on January 9, 2027, one-third on January 9, 2028, and one-third on January 9, 2029.
She was also granted options on 106,545 common shares with an exercise price of $6.56 per share, granted at $0 cost. These options vest one-third on January 9, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter, and expire on January 9, 2036. Following these grants, she directly holds the full amounts reported.
Alpha Cognition Inc. officer Henry Huy Du, VP Finance and Accounting, reported equity awards dated January 9, 2026. He acquired 20,579 common shares at a price of $0, reported as restricted stock units that vest one‑third on January 9, 2027, one‑third on January 9, 2028, and one‑third on January 9, 2029. He also received 15,982 common share options with an exercise price of $6.56 per share, vesting one‑third on January 9, 2027 and the remainder in equal quarterly installments, and expiring on January 9, 2036. After these grants, he beneficially owns 20,579 common shares and 15,982 options, all held directly.
Alpha Cognition Inc. (ACOG) reported an auditor transition following its move of principal executive offices to Texas. On October 10, 2025, Manning Elliott LLP resigned as independent registered public accounting firm due to licensing requirements in Texas.
The company states there were no disagreements with Manning Elliott on accounting, disclosure, or audit scope, and no reportable events under Regulation S‑K Item 304. Manning Elliott’s prior reports for fiscal years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified.
With Audit Committee approval on October 10, 2025, Alpha Cognition engaged CBIZ CPAs P.C., a U.S.-licensed, independent registered public accounting firm, and expects a seamless transition.
Alpha Cognition Inc. announced a change in independent auditor following its relocation of principal executive offices to Texas. Manning Elliott LLP resigned on October 10, 2025 due to administrative licensing requirements, as it is licensed in Canada but not in Texas. The company reports no disagreements on accounting principles, disclosure, or audit scope, and Manning Elliott’s audit reports for 2024 and 2023 were unmodified.
The Audit Committee approved the engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm on October 10, 2025. The company states it anticipates a seamless transition and filed Manning Elliott’s SEC letter as Exhibit 16.1, confirming agreement with the company’s statements.
Alpha Cognition Inc. received a Schedule 13G reporting that Opaleye Management Inc., Opaleye, L.P. and James Silverman together beneficially own 1,875,142 shares of Alpha Cognition common stock, representing 8.97% of the class based on 20,902,104 shares outstanding as cited. The filing shows no sole voting or dispositive power; instead the holders report shared voting and shared dispositive power over the reported shares. The statement clarifies the Adviser–Fund relationship and that Mr. Silverman exercises control over the Adviser, and includes a certification that the stake was not acquired to change control. Signatures are dated 10/03/2025 and the issuer address is listed in Grapevine, Texas.
Alpha Cognition Inc. entered into an underwriting agreement to sell 4,651,516 common shares at $6.25 per share and pre-funded warrants to purchase up to 948,484 common shares at a public price of $6.249 per warrant with a $0.001 exercise price. The company granted the underwriter a 30‑day option to buy up to 840,000 additional common shares at the same public offering price, with closing expected on or about October 2, 2025, subject to customary conditions.
Alpha Cognition expects gross proceeds of approximately $35.0 million, before fees and expenses. The company plans to use the net proceeds to accelerate commercial launch, focusing on sales expansion, marketing, and strengthening payer coverage and reimbursement infrastructure in the Alzheimer’s treatment market. Directors and executive officers agreed to 75‑day lock‑ups restricting share sales after the offering closes.
Alpha Cognition Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., LLC, allowing the company to sell common shares from time to time with an aggregate gross sales value of up to US$75.0 million. Under this arrangement, Wainwright will act as sales agent and use commercially reasonable efforts to execute sales based on the company’s instructions, earning a commission of up to 3.0% of the gross sales price of shares sold.
Sales may be conducted as at-the-market offerings on the Nasdaq Capital Market or through ordinary brokers’ transactions as permitted under Rule 415 of the Securities Act. Alpha Cognition is not obligated to sell any shares and may suspend or terminate the program at any time.